Sintilimab + IL-2 Combined with CAPOX

DRUG2 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Solid TumorRadiotherapyRectal Cancer

Phase 2

Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)

Active, not recruitingNCT06577194

The First Affiliated Hospital with Nanjing Medical UniversityAdvanced Solid Tumor, Rectal Cancer

Start: 2024-10-09End: 2029-01-15Updated: 2026-08-10

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

RecruitingNCT07646639

The First Affiliated Hospital with Nanjing Medical UniversityRadiotherapy, Rectal Cancer

Start: 2026-05-20End: 2030-12-31Target: 122Updated: 2026-06-15